


# COPY

17248-004002 (4804B)	Mooreland and Moore on October 26, 2004	October 25, 2004	For PTO Use Only Do Not Mark in This Area
Application No. 10/849,664	Filing Date May 19, 2004	Attorney/Secretary Init SZS/SWP/kzf	1
DIAGNOSIS AND	MICROORGANISMS THERAPY OF DISEAS OR INFLAMED TISSI	SES ASSOCIATED	·
Applicant Aladar Szalay et al.			
	I page in duplicate);		
·Information Disclos ·Form PTO-1449 (19	sure Statement (2 pages) 9 pages)		
•	Boxes containing 6 vol	umes)	
<b>(</b> A)			



Frederick P. Fish 1855-1930

W.K. Richardson 1859-1951

October 25, 2004

12390 El Camino Real San Diego, California 92130

Telephone 858 678-5070

Facsimile 858 678-5099

Web Site www.fr.com

Stephanie Seidman (858) 678-4777

SEIDMAN@FR.COM

Mooreland & Moore 2001 Jefferson Davis Hwy. Suite 302 Arlington, VA 22202

Re: LIGHT EMITTING MICROORGANISMS AND CELLS FOR DIAGNOSIS AND THERAPY OF DISEASES ASSOCIATED WITH WOUNDED OR INFLAMED TISSUE

BOSTON

DALLAS

Our Ref.:

17248-004002 (4804B)

DELAWARE

NEW YORK

SAN DIEGO

SILICON VALLEY

TWIN CITIES

WASHINGTON, DC

Dear Gentlemen:

Please deliver the enclosed documents to the U.S. Patent and Trademark Office Mail Room on Tuesday, October 26, 2004. The documents enclosed are a Transmittal letter, Information Disclosure Statement; Form PTO-1449 (19 pages); Cited References (2 boxes containing 6 volumes), and a return postcard. In addition, please have the enclosed postcard date-stamped by the PTO and returned to us at your earliest convenience. We would also appreciate receiving a confirmation from you indicating that delivery of the enclosed documents has been made.

Thank you for your assistance in this matter. If you have any questions, please do not hesitate to contact our office.

Sincerely,

Stephanie L. Seidman

SZS/SWP/kzf

10449280.doc



Attorney's Docket No.: 17248-004002 / 4804B

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Aladar Szalay et al.

Art Unit: 1632

Serial No.: 10/849,664

Examiner: Unknown

Filed : May 19, 2004

Conf. No.: 7765

Cust. No. : 20985

Title

: LIGHT EMITTING MICROORGANISMS AND CELLS FOR DIAGNOSIS

AND THERAPY OF DISEASES ASSOCIATED WITH WOUNDED OR

**INFLAMED TISSUE** 

Mail Stop: Amendment Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## TRANSMITTAL LETTER

#### Dear Sir:

Transmitted herewith are an Information Disclosure Statement and Forms PTO-1449 (19 pages) and copies of non US patent cited references for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a first office action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:

冈 The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

Stephanie L. Seidman

Dated: October 25, 2004

Attorney Docket No. 17248-004002 (4804B)

Address all correspondence to:

Stephanie L. Seidman Fish & Richardson P.C. 12390 El Camino Real

San Diego, California 92130 Telephone: (858) 678-5070 Facsimile: (202) 626-7796

Email: seidman@fr.com

10449271.doc

Attorney's Docket No.: 17248-004002 / 4804B



Applicant: Aladar Szalay et al. Art Unit : 1632 Serial No.: 10/849,664 Examiner: Unknown Conf. No.: 7765 Filed : May 19, 2004

Cust. No. : 20985

: LIGHT EMITTING MICROORGANISMS AND CELLS FOR DIAGNOSIS AND Title

THERAPY OF DISEASES ASSOCIATED WITH WOUNDED OR INFLAMED

TISSUE

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. 1.97-1.98

Dear Sir:

Because this Information Disclosure Statement is filed before the receipt of a First Office Action on the Merits for the above-captioned application a fee is not required. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (19 pages) and copies of the cited non U.S. Patent documents are provided herewith.

The documents cited on the Forms PTO-1449 are in the English language, with the exception of Items BI and HA. Item BI (International Application Publication No. WO 94/10302) is in the German language and is supplied with an English language Derwent abstract (Item DR). Item HA, article by Li et al., is in the Chinese language and is supplied with an English abstract on the last page of the article. Hence, in accordance with the requirements of 37 C.F.R. 1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following pending U.S., European and International applications that have one or more common inventors and/or are commonly owned:

Attorney's Docket No.: 17248-004002 / 4804B

Applicant: Aladar Szalay et al. Serial No.: 10/849,664 Filed: May 19, 2004 Information Disclosure Statement

Page : 2 of 2

Application No.	Filing Date	Matter No.
US 10/872,156	06/18/04	002001
US 10/866,606	06/10/04	003002
PCT/US04/19866	06/18/04	002WO1
EP 03013826.7	06/18/03	002EP1
EP 02012552.2	06/05/02	004EP1
EP 020794632.6	01/28/04	003EP3
EP 03018478.2	08/14/03	005EP1
EP 03024283.8	10/22/03	006EP1

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R., 1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R., 1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and they be made of record in the file history of the above-captioned application.

Respectfully submitted,

Stephanie L. Seidman Reg. No. 33,779

Dated: October 25, 2004

Attorney Docket No. 17248-004002 (4804B)

Address all correspondence to:

Stephanie L. Seidman Fish & Richardson P.C. 12390 El Camino Real San Diego, California 92130

Telephone: (858) 678-5070 Facsimile: (202) 626-7796 Email: seidman@fr.com

10449270.doc

Substitute Form PTO-1449, U.S. Separtment of Continue (Modified)

U.S. Separtment of Continue (Continue (C

Attorney's Docket No. 17248-004002

Application No. 10/849,664

## List of Patents and Publications for Applicant's **Information Disclosure Statement**

Applicant Szalay, et al.

Filing Date May 19, 2004

**Group Art Unit** 1632

(37 CFR §1.98(b))

<u> </u>	U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate	
	Α	2003/0228261	12/11/03	Szalay et al.	424	9.34	06/05/02	
	В	2003/0213007	11/13/03	Slattery et al.	800	15	03/26/03	
	С	2002/0160970	10/31/02	Hadlaczky et al.	514	44	03/05/01	
	D	2002/0160410	10/31/02	Hadlaczky et al.	435	6	04/17/02	
	E	2004/0143861	07/22/04	Hadlaczky et al.	800	14	02/18/04	
	F	2003/0133949	07/17/03	Szalay et al.	424	200.1	01/30/03	
	G	2003/0101480	05/29/03	Hadlaczky et al.	800	278	11/01/02	
	Н	2003/0083293	05/01/03	Hadlaczky et al.	514	44	05/16/02	
	I	2003/0059400	03/27/03	Szalay	424	93.2	07/03/02	
	J	2003/0033617	02/13/03	Hadlaczky et al.	800	6	04/17/01	
	K	2001/0029023	10/11/01	Szalay et al.	435	7.1	01/25/01	
	L	2001/0008025	07/12/01	Hadlaczky et al.	800	8	06/12/98	
	М	4,442,203	04/10/84	Varshavsky	435	6	06/30/81	
	N	4,778,759	10/18/88	Szalay et al.	435	477	01/09/85	
	0	5,221,623	06/22/93	Legocki et al.	435	252.3	07/19/89	
	P	5,283,187	02/01/94	Aebischer et al.	435	182	01/08/91	
	Q	5,300,436	04/05/94	Goldstein et al.	435	190	01/26/93	
	R	5,550,050	08/27/96	Holland et al.	435	382	04/15/94	
	S	5,639,275	06/17/97	Baetge et al.	604	891.1	05/25/95	
	Т	5,650,148	07/22/97	Gage et al.	424	93.2	03/10/94	
	U	5,653,975	08/05/97	Baetge et al.	424	93.1	05/25/95	
	V	5,656,481	08/12/97	Baetge et al.	435	325	05/25/95	
	w	5,676,943	10/14/97	Baetge et al.	424	93.21	05/25/95	
	х	5,704,910	01/06/98	Humes	604	502	06/05/95	
	Y	5,750,103	05/12/98	Cherksey	424	93.21	06/02/95	
	Z	5,756,455	05/26/98	Kinzler et al.	514	12	02/17/95	
	AA	5,762,959	06/09/98	Soon-Shiong et al.	424	451	12/23/94	

**Examiner Signature** 

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 U.S. Department of Commerce Attorney's Docket No. Application No. (Modified) Patent and Trademark Office 17248-004002 10/849,664 Applicant List of Patents and Publications for Applicant's Szalay, et al. **Information Disclosure Statement** Filing Date Group Art Unit May 19, 2004 1632 (37 CFR §1.98(b)) **U.S. Patent Documents** Desig. Publication Filing Date Examiner Document **Subclass** Initial ID Number Date **Patentee** Class If Appropriate 05/23/95 435 5,795,790 08/18/98 Schinstine et al. 382 AB 05/24/95 AC 08/25/98 Dionne et al. 424 422 5,798,113 AD 5,800,828 09/01/98 Dionne et al. 424 422 01/10/94 424 422 05824/95 09/01/98 Dionne et al. **AE** 5,800,829 Schinstine et al. 424 93.21 05/23/95 AF 5,833,979 11/10/98 AG 5,834,001 10/10/98 Dionne e tal. 424 422 05/24/95 Gentile et al. 424 06/07/95 AH 5,837,234 11/17/98 93.7 ΑI 5,840,576 11/24/98 Schinstine et al. 435 325 05/23/95 Wu 232 02/19/97 AJ 5,842,431 12/01/98 112 08/26/94 ΑK 12/29/98 Emerich et al. 604 500 5,853,385 93.21 05/23/95 AL 5,853,717 12/29/98 Schinstine et al. 424 456 10/22/92 AM 5,861,290 01/19/99 Goldsmith et al. 435 Szalay et al. 435 6 12/23/96 AN 5,976,796 11/02/99 08/07/96 AO 6,025,155 02/15/00 Hadlaczky et al. 435 69.1 AP 6,077,697 06/20/00 Hadlaczky et al. 435 172.3 07/15/96 23.7 AQ 6,080,849 06/27/00 Bermudes et al. 536 09/10/97 6,217,847 04/17/01 Contag et al. 424 9.1 01/19/99 AR Diamond et al. 23.1 05/09/97 AS 6,265,557 07/24/01 536 44 01/28/03 Weissleder et al. 514 04/21/00 AT 6,511,967 ΑU 6,713,293 03/30/04 Grummt et al. 435 182 02/08/99 06/01/04 800 06/12/98 ΑV 6,743,967 Hadlaczky et al. 25

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Desig. Document Publication Country or							Translation	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AW	00/47237	08/17/00	PCT				L
	AX	01/05229	1/25/01	PCT				
	AY	01/14579	03/01/01	PCT				

Examiner Signature

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office				Application No 10/849,664					
		d Publications n Disclosure St	for Applicant's tatement	Applicant Szalay, et al.	''				
(37 CFR §1.98(b))			Filing Date May 19, 2004		Group Art Unit				
	Foreig	n Patent Doc	uments or P	ublished Foreign P	atent A	Application	15		
Examiner	Desig.	Document	Publication	Country or				lation	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No	
	AZ	01/18195	03/15/01	PCT					
	BA	01/25399	04/12/01	PCT					
	ВВ	03/014380	02/20/03	PCT					
_	ВС	03/063593	08/07/03	PCT		•			
-	BD	03/104485	12/18/03	PCT A2					
	BE	1 281 767	05/28/03	EP					
	BF	1 281 772	02/05/03	EP A1					
	BG	1 369 491	12/10/03	EP					
	вн	91/07989	06/13/91	PCT					
	BI	94/10302	05/11/94	PCT				X*	

X\*= An English Language Derwent abstract is being provided

	<del></del>	ocuments (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.					
Initial	ID	Document				
	ВЈ	Advisory Committee on Immunization Practices (ACIP), "Smallpox vaccination and adverse reactions: guidance for clinicians", Morbidity and Mortality Weekly Report 52(RR-4): 1-29 (February 21, 2003)				
	Advisory Committee on Immunization Practices (ACIP), "Vaccinia (smallpox) vaccine:  BK recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, 5  10): 1-26 & ce1-ce7 (June 22, 2001)					
	BL Aebischer et al., "Long-Term Cross-Species Brain Transplantation of a Polymer-Encapsulated Dopamine-Secreting Cell Line," Experimental Neurology 111:269-275 (1991)					
	ВМ	BM Aebischer et al., "Functional Recovery in Hemiparkinsonian Primates Transplanted with Polym Encapsulated PC12 Cells," Experimental Neurology 126:151-158 (1994)				
	Aguilar, O.M. et al., "The <i>nifEN</i> genes participating in FeMo cofactor biosynthesis and genes encoding dinitrogenase are part of the same operon in <i>Bradyrhizobium</i> species. Mol Gen Genet. 224(3):413-20 (1990)					
	во	Alcamí, A. et al., "Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors", J. Gen. Virol., 80: 949-959 (1999)				
	ВР	Antoine, G. et al., "Characterization of the vaccinia MVA hemagglutinin gene locus and its evaluation as an insertion site for foreign genes", Gene, 177: 43-46 (1996)				
	BQ Arakawa, S. et al., "Clinical trial of attenuated vaccinia virus AS strain in the treatment of adva adeocarcinoma", J. Cancer Res. Clin. Oncol., 113: 95-98 (1987)					
_	BR	Baeksgaard, L. and J.B. Sorensen, "Acute tumor lyssi syndrome in solid tumorsa case report and review of the literature", Cancer Chemother. Pharmacol., 51: 187-192 (2003)				
	BS	Baker, R.O. et al., "Potential antiviral tehrapeutics for smallpox, monkeypox, and other orthopoxvirus infections", Antiviral Research, 57: 13-23 (2003)				

Examiner Signature	Date Considered		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Substitute For (Modified)	Substitute Form PTO-1449 Modified)  U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17248-004002	Application No. 10/849,664	
		d Publications for Applicant's n Disclosure Statement	Applicant Szalay, et al.		
(37 CFR §1.98	R(b))		Filing Date May 19, 2004	Group Art Unit 1632	
		ocuments (include Author,	Title, Date, and Place o	f Publication)	
Examiner Initial	Desig. ID		Document		
	BT	Balkwill, F., "Chemokine biology in o	cancer", Seminars in Immunol.,	15: 49-55 (2003)	
	BU	Baxby, D., "Poxviruses", Chapter 15 A.J. et al.(eds.), John Wiley & Sons L	.td., pp. 451-465 (2000)		
	BV	Beebe, J.L. and E.W. Koneman, "Rec Neoplastic Disease," Clin. Microbiol.	Rev., 8(3): 336-356 (1995)		
	BW	Beerntsen, B.T. et al., "Genetics of M 115-137 (2000)			
	BX	Belas et al., "Bacterial Bioluminescen Vibrio harveyi," Science, 218: 791-79	93 (1982)		
	BY	Bell, J.C. et al., "Getting oncolytic vir			
	BZ	Bendig, M.M., "The production of foreigh proteins in mammalian cells," Genetic Engineering 127 (1988)			
	CA	Bergsland, E.K. and A.P. Venook, "S. J. Clin. Oncol., 20(9): 2220-2222 (200	02)		
	СВ	Bermudes et al., "Live bacteria as anti- Current Opinion in Drug Discovery &			
	СС	Best et al., "Baboon/human homologi comparison," Cytogenet Cell Genet. 8	32(1-2):83-7 (1998)		
	CD	Bickels, J. et al., "Coley's toxin: histor	rical perspective", Isr. Med. Asse	oc. J., 4(6): 471-472 (2002)	
	CE	Blanchard, T.J. et al., "Modified vacci and lacks several immunomodulatory General Virology, 79: 1159-1167 (19	proteins: implications for use as 98)	a human vaccine," Journal of	
	CF	Blasco, R. and B. Moss, "Selection of formation," Gene, 158: 157-162 (1995)	5)		
	CG	Bogdahn et al., "Autocrine Tumor Ce Melanoma", Cancer Research 49:535	8-5363 (1989)		
	СН	Borellini, F. and J.M. Ostrove, "The T Process Controls and Final Product To Applications and Regulations, A. Mea	esting", Chapter 18 in <i>Gene The</i> ager (Ed.), John Wiley & Sons L	rapy Technologies, td., pp. 359-373 (1999)	
	CI	Boulanger, D. et al., "Morphogenesis 81: 675-687 (2000)			
	CJ	Bouvier et al., "Functional characteriz virus as an expression system," Europ	ean Journal of Pharmacology 29	0(1):11-17 (1995)	
	CK	Boyd, J.E., "Facilities for Large-Scale Gene Therapy Technologies, Applicat	ions and Regulations, A. Meage	r (Ed.), pp. 383-400 (1999)	
	CL	Brain, J.D. et al., "Pulmonary intravas phagocyte system in 13 species", Am.	J. Physiol., 276(1 pt 1): L146-L	.154 (1999)	
	СМ	Breman, J.G. and D.A. Henderson, "D. 346(17): 1300-1308 (2002)			
	CN	Broder, C.C. et al., "Expression of for recombinant vaccinia virus vectors", (		imary macrophages using	

Examiner Signature	Date Considered				
EXAMINER: Initial if citation considered, whether or not citation is in co	I onformance with MPEP 609; Draw line through citation if not in				
conformance and not considered. Include copy of this form with next communication to applicant.					

Substitute Form PTO-1449  (Modified)  U.S. Department of Commerce Patent and Trademark Office			Attorney's Docket No. 17248-004002	Application No. 10/849,664		
		nd Publications for Applicant's on Disclosure Statement	Applicant Szalay, et al.			
			Filing Date	Group Art Unit		
(37 CFR §1.98			May 19, 2004	1632		
		ocuments (include Author,	<u> Title, Date, and Place o</u>	f Publication)		
Examiner Initial	Desig. ID		Document			
	co	Broyles, S.S., "Vaccinia virus transcri	iption", Journal of General Virol	ogy, 84: 2293-2303 (2003)		
	СР	Brunke M et al., "Luciferase assembly molecular chaperones and peptidyl-pr (1996)	olyl cis/trans-isomerases," J Bio	l Chem. 271(38):23487-94		
	CQ	Carroll, S.F. and R.J. Collier, "Active 262:8707-8711 (1987)				
	CR	Carter, G.C. et al., "Vaccinia virus con Virology, 84: 2443-2458 (2003)		· · · · · · · · · · · · · · · · · · ·		
	CS	Cavanagh, L.L. and U.H. von Andrian dendritic cells", Immunology and Cel		ne origins and destinations of		
	СТ	Chalfie et al., "Green Fluorescent Pro (1994)	Chalfie et al., "Green Fluorescent Protein as a Marker for Gene Expression," Science 263: 802-80			
	CU	Chambers, A.F. et al., "Dissemination and Growth of Cancer Cells in Metastatic Sites," Nat. Rev. Cancer, 2: 563-572 (2002)				
	CV	Chambers, A.F. et al., "Molecular bio experimental studies on metastatic ine				
	CW	Chaudhary et al., "Role of domain II of periplasm and medium by Escherichia	of Pseudomonas exotoxin in the	secretion of proteins into the		
	CX	Cheadle, E.J. and A.M. Jackson, "Bug	gs as Drugs for Cancer", Immuno	ol., 107: 10-19 (2002)		
	DA	Chen et al. "Evaluation of combined vand IL-12 in a glioma model." Cancer	Gene Ther. 7(11):1437-47 (200	0)		
	DB	Chen et al. "Cancer gene therapy by d thymidine kinase gene," Hum Gene T	her. 9(5):729-36 (1998)			
• "-	DC	Chiocca, E.A., "Oncolytic Viruses", N	Nat. Rev. Cancer, 2(12): 938-950	(2002)		
	DD	Choi et al., "Efficient secretory production of alkaline phosphatase by high cell density culture of recombinant <i>Escherichia coli</i> using the <i>Bacillus</i> sp. endoxylanase signal sequence," Appl. Microbiol. Biotechnol. 53:640-645 (2000)				
	DE	Cichutek, K., "Development and Regulation of Gene Therapy Drugs in Germany", Chapter 17 in Gene Therapy Technologies, Applications and Regulations, A. Meager (Ed.), John Wiley & Sons Ltd. pp. 347-358 (c1999)				
	DF	Clairmont, C. et al., "Enhanced antitum endostatin," American Association for 1-5, 2000, 41:732 Abstract #4653 (20)	r Cancer Research: 91st Annual 00)	Meeting of the AACR, April		
	DG	Compton, J.L. and A.A. Szalay, "Inserby homologous recombination with a (1982)	cotransforming plasmid," Mol C	Gen Genet. 188(1):44-50		
	DH	Condeelis, J. and J.E. Segall, "Intravit 921-930 (2003)				
	DI	Contag et al., "Photonic detection of bacterial pathogens in living hosts," Mol. Microbiol. 18: 593-603 (1995)				

Examiner Signature	Date Considered				
	<u></u>				
EXAMINER: Initial if citation considered, whether or not citation is in co	informance with MPEP 609; Draw line through citation if not in				
conformance and not considered. Include copy of this form with next communication to applicant.					

Substitute For (Modified)	m PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002	Application No. 10/849,664	
		d Publications for Applicant's n Disclosure Statement	Applicant Szalay, et al.		
(37 CFR §1.98	3(b))		Filing Date May 19, 2004	Group Art Unit 1632	
(5) 5) 1, 5	Other D	ocuments (include Author, 1	Title, Date, and Place o	f Publication)	
Examiner Initial	Desig. ID	_	Document		
	DJ	Coupar, B.E.H. et al., "A general metl expressing multiple foreign genes", G	ene, 68: 1-10 (1988)		
	DK	Coussens, L.M. and Z. Werb, "Inflam	mation and cancer", Nature, 420	): 860-867 (2002)	
	DL	Craperi et al. "Increased bax expression herpes thymidine kinase gene-express	ing glioma cell line." Hum Gene	e Ther. 10(4):679-688 (1999)	
	DM	Cseh, S. et al., "Rapid freezing of mostages," Acta Veterinaria Hungarica 4	4(4):457-65 (1996)		
	DN	Culver et al., "In vivo gene transfer w experimental brain tumors." Science.	256(5063):1550-2 (1992)		
	DO	Davis, C. et al., "The role of inflamma Haemostasis, 1: 1699-1709 (2003)			
	DP	De Clercq, E., "Cidofovir in the theragin Pharmacological Sciences, 23(10):	456-458 (2002)		
	DQ	Demers, G.W. et al., "Pharmacologic Cancer Res., 63: 4003-4008 (2003)			
	DR	Derwent English abstract for WO 94/10302, published May 11, 1994 entitled: "Vectors inhibiting HIV replication in potential host cells – contg. DNA encoding Pol, Gag, Env, Rev, and/or Tat in antisense direction and further DNA causing spontaneous amplification," Accession Nbr. 1994-152544 [19]			
	DS	de Wet et al., "Firefly Luciferase Gen- Biol. 7: 725-737 (1987)	_		
	DT	Diamond, D.C. ET AL. "Sequence co found in O alleles differ between hum	an and baboon," Blood Cells M	ol Dis. 23(2):242-51 (1997)	
_	DU	Diamond, D.C., et al., "Genotying the fluorescence SSCP," Biotechniques 2'	7(5):1054, 1056, 1058-59, 1061	(1999)	
	DV	Dietrich, G. et al., "Delivery of antige attenuated suicide Listeria monocytog	enes," Nat Biotechnol. 16(2):18	1-5 (1998)	
	DW	Ding et al., "Zinc-dependent dimers o Sci. USA 95:10443-10448 (1998)			
	DX	Dobbelstein, M., "Viruses in therapy-	- royal road or dead end?", Viru	s Research, 92: 219-221 (2003)	
	DY	Domi, A. and B. Moss, "Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells", Proc. Natl. Acad. Sci. U.S.A., 99(19): 12415-12420 (2002)			
	DZ	Dull et al., "Insulin-like growth factor therapy," Nature 310: 777-781 (1984)			
	EA	Eastham et al. "Prostate cancer gene the transduction followed by ganciclovir in 7(4):515-23 (1996)	n mouse and human prostate ca	ncer models." Hum Gene Ther.	
	EB	Ehrengruber, M.U., "Alphaviral gene 22 (2002)			
	EC	Engebrecht et al., "Measuring Gene E	xpression with Light," Science	227: 1345-1347 (1985)	

Examiner Signature	Date Considered		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation conformance and not considered. Include copy of this form with next communication to applicant.

Substitute For (Modified)	m PTO-144	9 U.S. Department of Commerce Patent and Trademark Office	Attomey's Docket No. 17248-004002	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement			Applicant Szalay, et al.	
(37 CFR §1.98	3(b))		Filing Date May 19, 2004	Group Art Unit 1632
		ocuments (include Author,	Title, Date, and Place o	f Publication)
Examiner Initial	Desig. ID		Document	
	EA	Escher, A. et al., "Bacterial luciferase sensitive in vivo to elevated temperatu	ire," Proc Natl Acad Sci U S A.	86(17):6528-32 (1989)
	EB	Escher, A et al., "The β subunit polyp 42° C," Mol Gen Genet. 230(3):385-9	93 (1991)	_
	EC	Escher, A. and A.A. Szalay, "GroE-m Genet. 238(1-2):65-73 (1993)	-	•
	ED	Esposito, J.J. and F. Fenner, "Poxvirus 2885-2921. Edited by D. M. Knipe an (2001)	d P. M. Howley, Philadelphia: I	Lippincott Williams & Wilkins,
	EE	Fatyol, K et al., "Mer22-related seque primates," Mol Gen Genet. 262(6):93	1-9 (2000)	
	Fatyol, K et al. "Molecular characterization of a stably transformed <i>Bombyx mori</i> cell line: identification of alternative transcriptional initiation sites of the A3 cytoplasmic actin gene." M Gen Genet. 260(1):1-8 (1998)		toplasmic actin gene." Mol	
	EG Fatyol, K et al., "An alternative intronic promoter of the Bombyx A3 cytoplasmic actin gene exh a high level of transcriptional activity in mammalian cells," Mol Gen Genet. 261(2):337-45 (199		Genet. 261(2):337-45 (1999)	
	Fatyol, K and A.A. Szalay, "The p14 <sup>ARF</sup> tumor suppressor protein facilitates nucleolar sequestra of hypoxia-inducible factor-1α (HIF-1α) and inhibits HIF-1-mediated transcription," J Biol Che 276(30):28421-28429 (2001)		I transcription," J Biol Chem.	
	EI	Fernández-Piñas, F. and C.P. Wolk, "I exogenous aldehyde for in vivo localization of the control		
	EJ	Fidler, I.J., "The pathogenesis of cancer Research, 3: 1-6 (2003)	er metastasis: the 'seed and soil'	hypothesis revisited", Nature
	EK	Foran, D.R. and W.M. Brown, "Nucle bioluminescent marine bacterium Vibr		
	EL	Forbes, N.S. et al., "Sparse Initial Entrangement Leads to Heterogenous Accumulation		
	Fox, A.W., "Emergency and Compassionate-use INDs and Accelerated NDS or ANDA Approva EM Procedures, Benefits and Pitfalls", Chapter 26 in Principles and Practice of Pharmaceutical Medicine, A.J. Fletcher, et al.(Eds.), John Wiley & Sons, pp.299-305, (2002)			d NDS or ANDA Approvals ce of Pharmaceutical , (2002)
	EN Freed et al., "Survival of Implanted Fetal Dopamine Cells and Neurologic Improvement 12 to 46  Months After Transplantation for Parkinson's Disease," New England Journal of Medicine 327:1549-1555 (1992)			Journal of Medicine
	EO	Freitag, N.E. and K.E. Jacobs, "Exami Expression by Using Green Fluorescent (1999)	nt Protein of Aequorea victoria,	" Infect.Immun. 67:1844-1852
	EP	Friberg, S. and S. Mattson, "On the Gr Medical Decision Making," Journal of		
	EQ	Gallagher, R., "Vaccination Undermin		
	ER Geng, J.G., "Directinal migration of leukocytes: their pathological roles in inflammation and strategies for development of anti-inflammatory therapies", Cell Res., 11(2): 85-88 (2001)			

Examiner Signature	Date Considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in				
conformance and not considered. Include copy of this form with next communication to applicant.				

Substitute For (Modified)	m PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attomey's Docket No. 17248-004002	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Szalay, et al.		
(37 CFR §1.98	3(b))		Filing Date May 19, 2004	Group Art Unit 1632
		ocuments (include Author, 1	Title, Date, and Place o	f Publication)
Examiner Initial	Desig. ID		Document	
	ES	Geng, J.G., "Interaction of vascular er inflammation, thrombosis and cancer 1300 (2003)	growth and metastasis," Acta Ph	narmacol. Sin, 24(12): 1297-
	ET	Giacomin, L.T. and A.A. Szalay, "Expanded Arabidopsis thaliana in response to in (1996)	fection by phytopathogenic bact	eria," Plant Sci. 116: 59-72
	EU	Gnant, M.F.X. et al, "Tumor-Specific Model of Liver Metastases", Journal of		
	EV	Goetz et al., "Multicenter Study of Au Striatum in Patients with Advanced Pa		
EW Goetz, M et al., "Microinjection and g Proc Natl Acad Sci U S A. 98(21):122		rowth of bacteria in the cytosol		
		Of Intravesical Vaccinia Virus As A Vector For Gene Therapy		
	Gómez, C.E. and M. Esteban, "Recombinant proteins produced by vaccinia virus vectors can incorporated within the virion (IMV form) into different compartments," Arch. Virol., 146: (2001)		s," Arch. Virol., 146: 875-892	
Graff, C.P. and K.D. Wittrup, "Theoretical Analysis of Antibody Targeting of Tumor Spheroic Importance of Dosage for Penetration, and Affinity for Retention", Cancer Res., 63: 1288-129 (2003)		ncer Res., 63: 1288-1296		
	FA	Gray, J.W., "Evidence emerges for ear tumors", Cancer Cell, 4(1): 4-6 (2003)		tion of primary and metastatic
ì	FB	Green, D.R. and G.I. Evan, "A matter	of life and death", Cancer Cell,	1: 19-30 (2002)
	FC	Greer III, L.F. and A.A. Szalay, "Imag living cells and organisms: a review,"		
	FD	Griffin, D.E., "A Review of Alphaviru Reviews, 22(6): 721-723 (1998)	us Replication in Neurons", Neu	roscience and Biobehavioral
	FE	Guy et al., "Expression of the neu proinduces metastatic disease," Proc. Nat	tooncogene in the mammary epi 1. Acad. Sci.USA 89: 10578-10	thelium of transgenic mice 582 (1992)
	FF		prodrug therapy using CB1954" Anti-Cancer Drug Design	
	FG	Hacein-Bey-Abina, S. et al., "A Seriou Severe Combined Immunodeficiency"	ous Adverse Event after Successful Gene Therapy for X-Linked v". N. Engl. J. Med., 348(3): 255-266 (2003)	
	FH		f DNA regions adjacent to nifKDH homologous sequences in	
	FI	Haghighat et al. "Antitumor effect of l Anticancer Res. 20(3A):1337-42 (200	IL-2, p53, and bax gene transfer	
	FJ	Hall et al., "Adenovirus-mediated hern therapy leads to systemic activity again mouse model of prostate cancer," Int J	pes simplex virus thymidine kin nst spontaneous and induced me	
FK Halsell, J.S. et al., "Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naïve U Military Personnel", J. Am. Med. Assoc., 289(24): 3283-3289 (2003)			Among Vaccinia-Naïve US	

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in co	nformance with MPEP 609: Draw line through citation if not in

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not it conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)  U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17248-004002	Application No. 10/849,664	
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Szalay, et al.		
			Filing Date	Group Art Unit
(37 CFR §1.98			May 19, 2004	1632
	· · · · · · · · · · · · · · · · · · ·	ocuments (include Author,	litle, Date, and Place o	f Publication)
Examiner Initial	Desig.		Document	
	FL	Hanahan, D. and R.A. Weinberg, "Th	e Hallmarks of Cancer", Cell, 10	00: 57-70 (2000)
	FM	Hansen, R.M. and J.A. Libnoch, "Ren Vaccination", Arch. Intern. Med., 138	3: 1137-1138 (1978)	
	FN	Hawkins, L.K. et al., "Oncolytic bioth 17-26 (2002)		
	FO	Hemann et al., "High-Copy Expression DNA and Cell Biology 13:437-445 (1	994)	
	FP	Hermiston, T.W. and I. Kuhn, "Armed oncolytic viruses with therapeutic gen	es", Cancer Gene Therapy, 9: 10	022-1035 (2002)
	FQ	Hershey, P. et al., "Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccin Viral Lysates of Melanoma: Results of a Randomized Trial", Journal of Clinical Oncology, 20(20) 4181-4190 (2002)		
	FR	Hess et al., "Listeria monocytogenes pattenuated Salmonella typhimurium,"		
	FS	Hollinshead, M. et al., "Vaccinia virus utilizes microtubules for movement to the cell surface," Journal of Cell Biology, 154: 389-402 (2001)		
	FT Holló, G et al., "Evidence for a megareplicon covering megabases of centromeric chromosome Segments," Chromosome Res. 4(3):240-7 (1996)			
FU Hosokawa et al., "Pituitary Carcinoma of Pars Distalis as a Common Neoplasm in Fischer-Rats," Toxicol. Pathol. 21: 283-287 (1993)		Neoplasm in Fischer-344		
	Hughes, R.G. and N. Turner, "Financial Aspects of Clinical Trials", Chapter 42 in <i>Principles of Practice of Pharmaceutical Medicine</i> , A.J. Fletcher, et al.(eds.), pp. 501-512, John Wiley & S Ltd. (2002)		Chapter 42 in <i>Principles and</i> 01-512, John Wiley & Sons,	
	FW	Humlova, Z. et al., "Vaccinia virus ine 83: 2821-2832 (2002)		
	FX	Jain, R.K. and B.T. Fenton, "Intratum Malfunction?", Journal of the Nationa	l Cancer Institute, 94(6): 417-42	21 (2002)
	FY	Jain, R.K., "Molecular regulation of v		` ·
	FZ	Jemal, A. et al., "Cancer Statistics, 20		
	GA	Jeong, K.J. and S.Y. Lee, "Secretory I Biotechnol.Bioeng. 67:398-407 (2000)	0)	
	GB	Kaniga et al., "Homologs of the Shige typhimurium Entry into Cultured Epit		
	GC	Kawa, A. and S. Arakawa, "The Effect Myeloma; A Case Report", Japan. J. F.	Exp. Med. 58(1): 79-81 (1987)	
	GD	Keith, K.A. et al., "Evaluation of Nuc Inhibition of Orthopoxvirus Replication	on," Antimicr. Agents Chemothe	era., 47(7): 2193-2198 (2003)
	GE	Keresó, J. et al., "De novo chromoson region of mouse chromosomes," Chro	mosome Res. 4(3):226-39 (1996	6)
	C.F.	Kern, E.R., "In vitro activity of potent		

Examiner Signature	Date Considered		
EXAMINER: Initial if citation considered, whether or not citation is in co	onformance with MPEP 609; Draw line through citation if not in		
conformance and not considered. Include copy of this form with next communication to applicant.			

Substitute Form,PTO-1449  (Modified)  U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17248-004002	Application No. 10/849,664	
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Szalay, et al.		
			Filing Date	Group Art Unit
(37 CFR §1.9	8(b))		May 19, 2004	1632
		ocuments (include Author,	L	f Publication)
Examiner	Desig.	The state of the s	ritio, Dato, and Flace o	11 ublication,
Initial	ID ID	· ·	Document	
	GG	Kihara, A. and I. Pastan, "Analysis of Toxin Composed of Pseudomonas Ex 532-538 (1994)	Sequences Required for the Cytotoxin and Transforming Growt	h Factor α," Bioconj.Chem. 5:
	GH	Kim, E.M. et al., "Overview analysis or results from vaccinia melanoma oncol	of adjuvant therapies for melano lysate adjuvant therapy trials", S	maFa special reference to urgical Oncology, 10: 53-59
,	GI	(2001)  Kleer, C.G. et al., "Molecular biology clinical syndrome and molecular determination."	of breast cancer metastasis Infla	ammatory breast cancer:
· · · · · · · · ·	GJ	Kneissl, M. et al., "Interaction and ass mouse cells," J Mol Biol. 327(1):111-	embly of murine pre-replicative	complex proteins in yeast and
	GK	Kolowsky K.S. et al., "Length of foreign DNA in chimeric plasmids determines the efficiency of its		
	GL Kondo et al., "Activity of Immunotoxins Constructed with Modified Pseudomonas Exotoxin A Lacking the Cell Recognition Domain," J.Biol.Chem. 263: 9470-9475 (1988)			(1988)
GM Krauss, O. et al., "An investigation of particles", Journal of General Virology		incorporation of cellular antigen y, 83: 2347-2359 (2002)	ns into vaccinia virus	
GN Kruse, M, et al., "Enzyme assembly after de molecular chaperones and immunophilins,"				
	GO	Kubes, P., "Introduction: The complex 72 (2002)	•	·
	GP	Kunkel, E.J. and E.C. Butcher, "Plasm (2003)		
	GQ	Kwak, H. et al., "Poxviruses as vectors Develop., 6(2): 161-168 (2003)		
	GR	Langridge W.H. et al, "Detection of balight video image analysis," J Virol M	ethods. 61(1-2):151-6 (1996)	•
	GS	Langridge W.H. et al., "Uptake of DN Methods Enzymol. 153:336-50. (1987)	)	•
	GT	Langridge, W.H. and , A.A.Szalay, "B cells," Chapter 37 in Methods Mol Bio	ol. 82:385-96.(1998)	
	GU	Larson et al. "Triumph over mischance 38(8):1230-3 (1997)		
1	GV	Lawrence J.C., "The bacteriology of be	urns", J. of Hospital Infection 6:	: 3-17 (1985)
	GW	Lee et al., "The lux genes of the luminoponyfish," Eur. J. Biochem. 201: 161-1	ous bacterial symbiont <i>Photobac</i> 167 (1991)	cterium leiognathi, of the
	GX	Legocki et al., "Bioluminescence in soybean root nodules: Demonstration of a general approach to assay gene expression in vivo by using bacterial luciferase," Proc. Natl. Acad. Sci 83: 9080-9084		
GY (1986)  Ley, K., "Integration of inflammatory signals by rolling neutrophils", Immunological Review 8-18 (2002)			mmunological Reviews, 186:	

l	Examiner Signature	Date Considered	
ı			
ŀ	EXAMINER: Initial if citation considered, whether or not citation is in co	onformance with MPEP 609: Draw line through citation if not in	
	conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute For (Modified)	m PTO-144	9 U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement			Applicant Szalay, et al.	
(37 CFR §1.98	3(b))		Filing Date May 19, 2004	Group Art Unit 1632
		ocuments (include Author, 1	Title, Date, and Place o	f Publication)
Examiner Initial	Desig. ID		Document	
	GZ	Ley, K., "The role of selectins in infla (2003)		
	НА	Li et al "An engineered and assembled antibody directed against type IV colla abstract on last page of article]	agenase" Yaoxue Xuebao 35(7)	488-91 (July, 2000) [English
	нв	Lindvall et al., "Grafts of Fetal Dopan Parkinson's Disease," Science 237:574	4-577 (1990)	
	HC	Liu, H et al., "Detection of GDNF sec in the brains of live animals," Mol Ge	net Genomics. 266(4):614-23. (2	2001)
	HD Liu, J. et al., "Visualizing and quantifying protein secretion using a Renilla luciferase-GFP protein," Luminescence. 15(1):45-49 (2000)			
HE Lorenz et al., "Isolation and expression of a cDNA encoding Renilla reniformis lucifer USA 88: 4438-4442 (1991)		•		
	HF	Lorenz et al., "Expression of the Renilla reniformis luciferase gene in mammalian cells," J Bio Chemilumin. 11(1):31-7 (1996)		· · · · · · · · · · · · · · · · · · ·
	HG	Louie, A.Y. et al., "In vivo visualization of gene expression using magnetic resonance imaging Nature Biotechnology, 18: 321-325 (2000)		
	нн	Luscinskas, F.W. et al., "Leukocyte transendothelial migration: A junctional affair", Seminars Immunology, 14: 105-113 (2002)		<u> </u>
	HI Luscinskas, F.W. et al., "The role of endothelial cell lateral junctions during leukocyte trafficking Immunological Reviews, 186: 57-67 (2002)			
	HJ	Lusso, P., "Chemokines and Viruses:	The Dearest Enemies", Virology	y, 273: 228-240 (2000)
	нк	Lyford, J., "Gene therapy cause T-cell cell Leukemia in X-SCID gene therapy 4 (2003)		
	HL	MacDonald, I.C. et al., "Cancer spread for in vivo models", BioEssays, 24: 88	35-893 (2002)	
	НМ	MacLaren et al. "Receptive non-invasi animals" Gene Therapy (MacMillan F	Press)v.6 pp785-791, May (1995	5)
	HN	MacLeod R.A .et al., "Expression of g in Escherichia coli K-12," Arch Micro		Alteromonas haloplanktis 214
	но	Maeda, H. et al., "Tumor vascular perra review", J. Controlled Release, 65: 2	71-284 (2000)	<u>-</u>
	HP	Mahy, B.W.J., "An overview on the use of a viral pathogen as a bioterrorism agent: why smallpo Antivir. Res., 57: 1-5 (2003)		
	НQ	Maina C.V. et al., "Molecular weight of 702 (1984)		
	HR	Makower, D. et al., "Phase II Clinical" Adenovirus ONYX-015 in Patients with Cancer Res., 9: 693-702 (2003)	th Hepatobiliary Tumors with C	orrelative p53 Studies," Clin.
	HS	HS Mastrangelo, M.J. et al., "Poxvirus vectors: orphaned and underappreciated", J. Clin. Invest., 105(8): 1031-1034 (2000)		

Examiner Signature	Date Considered		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in			
conformance and not considered. Include copy of this form with next communication to applicant.			

				-
Substitute Form PTO-1449  (Modified)  U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 17248-004002	Application No. 10/849,664	
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Szalay, et al.		
			Filing Date May 19, 2004	Group Art Unit 1632
(37 CFR §1.98	Othor D	ocuments (include Author, 1	l	
Examiner	<del>,</del>	ocuments (include Author,	Title, Date, and Flace o	rubilcation)
Initial	Desig.	· ·	Document	
	нт	Matz et al., "Fluorescent proteins from 973 (1999)		species," Nat.Biotech. 17: 969-
	HU	Mayerhofer, R et al., "Monitoring of s zebrafish," J Biolumin Chemilumin. 1	0(5):271-5 (1995)	<u> </u>
	HV	McCart, J.A. et al., "Complex interact enzyme/prodrug effect of vaccinia-me	ediated tumor regression", Gene	Therapy, 7: 1217-1223 (2000)
	нw	McCart, J.A. et al., "Systemic Cancer Lacking Thymidine Kinase and Vacci (2001)	inia Growth Factor Genes", Can	cer Research, 61: 8751-8757
	нх	McDonald, D.M. and P.L. Choyke, "I Medicine, 9(6): 713-725 (2003)		
	НҮ	Meager, A. et al., "The Development of How it Affects Gene Therapy Product and Regulations, A. Meager (Ed.), Jol	ts", Chapter 16 in <i>Gene Therapy</i> hn Wiley & Sons Ltd., pp. 319-3	Technologies, Applications 346 (1999)
	Meighen, E.A. and R.B. Szittner, "Multiple		cteria," J. Bacteriol. 174(16):5371-5381 (1992)	
	IA	Mengaud et al., "Expression in Escher Determinant of Listeria monocytogene		
-	IB	Middleton, J. et al., "Leukocyte extravendothelium", Blood, 100(12): 3853-3	vasation: chemokine transport ar	
	IC	Moore et al., "Measuring transferring Biophysica Acta 1402(3):239-249 (19	receptor gene expression by NM	R imaging," Biochimica et
	ID	Moore, A.E., "Effects of Viruses on T	umors", Annu. Rev. Microbiol.,	8: 393-402 (1954)
	IE	Moretta, A., "Natural Killer Cells and Immunol., 2: 957-964 (2002)	Dendritic Cells: Rendezvous in	Abused Tissues", Nat. Rev.
	IF	Morris, D.W. et al., "Plasmid vectors 1(1):27-36 (1981)		_
	IG	Moss, B., "Poxviridae: the viruses and vol. 2, pp. 2849-2883. Edited by D. M & Wilkins, (2001)		
	IH	Moss, B., "Poxviridae: the viruses and 2637–2671. Edited by B. N. Fields, D (1996)		
	П	Mountz et al. "Technetium-99m NeoT FASEB J. 16(5):A1211 March Meetin	ig abstract (2002)	
	IJ	Nagahari et al. "Secretion into the cult use of the <i>ompF</i> gene for secretion of		
	IK	Nettleton, P.F. et al., "Parapoxviruses 205-208 (2000)	are strongly inhibited in vitro by	y cidofovir," Antivir. Res., 48:
Newton et al. "Expression and charac		cterization of recombinant human eosinophil-derived eurotoxin-anti-transferrin receptor sFv," J. Biol.		

Examiner Signature	Date Considered
EXAMINER: Initial if citation considered, whether or not citation is in co	oformance with MRED 600: Drow line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Chem.269(43):26739-45, (1994)

Substitute Form (Modified)	PTO-1449	9 U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002	Application No. 10/849,664
		d Publications for Applicant's n Disclosure Statement	Applicant Szalay, et al.	
			Filing Date	Group Art Unit
(37 CFR §1.98(I			May 19, 2004	1632
		ocuments (include Author, 1	<u> Fitle, Date, and Place o</u>	f Publication)
Examiner Initial	Desig. ID		Document	
	IM	Neyts et al., "Therapy and short-term perspectives", Antivir. Res. 57: 25-33	(2003)	
	IN	Nibbering et al. "Radiolabelled antimi Med Commun. 19(12):1117-21 (1998		infections: a review," Nucl
	IO	Nichterlein et al., "Clinafloxacin (CI 9 Murine Listeriosis and Salmonellosis,		
	IP	Nisato, R.E. et al., "Lymphangiogenes (2003)		
	IQ	Nolan G.P., et al., "Plasmid mapping (1984)	computer program," Nucleic Ac	ids Res. 12(1 Pt 2):717-29
	IR	Noti J.D. et al., "Organization and characterization of genes essential for symbiotic nitrogen fixation from Bradyrhizobium japonicum I110," J Bacteriol. 167(3):774-83 (1986)		
	IS	Noti J.D. et al., "Site-directed Tn5 and transplacement mutagenesis: methods to identify symbiotic nitrogen fixation genes in slow-growing Rhizobium," Methods Enzymol. 154:197-217 (1987)		
	IT	Ober, B.T. et al., "Immunogenicity and Safety of Defective Vaccinia Virus Lister:Comparison with Modified Vaccinia Virus Ankara", J. Virol., 76(15): 7713-7723 (2002)		
	IU	O'Kane et al., "Visualization of Bioluminescence as a Marker of Gene Expression in Rhizobium- Infected Soybean Root Nodules," J. Plant Mol. Biol. 10: 387-399 (1988).		
	IV	Olsson et al., "Engineering of monomeric bacterial luciferases by fusion of luxA and luxB genes in Vibrio harveyi," Gene 81(2):335-47 (1989)		
	IW	Olsson, O. et al., "The use of the <i>luxA</i> Gen Genet. 215(1):1-9 (1988)	gene of the bacterial luciferase	operon as a reporter gene,"Mol
	IX	Overholser et al., "Experimental Bacte Periodontitis," J. Infect. Dis. 155(1) (1		xtractions in Rats with
	ΙΥ	Padera, T.P. et al., "Lymphatic Metast 296: 1883-1886 (2002)	asis in the Absence of Function	al Intratumor Lymphatics",
	IZ	Paniacli, D. et al., "Vaccinia virus vec recombinant viruses and measurement	of gene expression", Gene, 47:	193-199 (1986)
	JA	Pardal, R. et al., "Applying the princip 895-902 (2003)	eles of stem-cell biology to cance	er," Nature Reviews Cancer, 3:
	ЛВ	Parish, C.R., "Cancer immunotherapy: Biology, 81: 106-113 (2003)	The past, the present and the fu	iture", Immunology and Cell
	JC	Pawelek, J.M. et al., "Bacteria as tumo (2003)	our-targeting vectors," The Lanc	et Oncology, 4: 548-556
	ло	Pecora, A.L. et al., "Phase I Trial of In Patients With Advanced Solid Cancers		
	JЕ	Peplinski, G.R. et al., "Vaccinia Virus North America, 7(3): 575-588 (1998)		
	JF	Pluen, A. et al., "Role of tumor-host in vs. subcutaneous tumors", Proc. Natl.		
	JG	Polverini et al., "Assay and Purificatio in Enzymology 198:440-450 (1991)		

Examiner Signature	Date Considered	
EXAMINER: Initial if citation considered, whether or not citation is in co	onformance with MPEP 609; Draw line through citation if not in	
conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute For (Modified)	m PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002	Application No. 10/849,664
		d Publications for Applicant's n Disclosure Statement	Applicant Szalay, et al.	
(37 CFR §1.98	3(b))		Filing Date May 19, 2004	Group Art Unit 1632
		ocuments (include Author, 1	Fitle, Date, and Place o	f Publication)
Examiner Initial	Desig. ID	·	Document	
	л	Pongor S. et al., "Microcomputer prog secondary structure from nucleotide so carboxylase sequences," DNA. 4(4):3	equence data: application to ribu 19-26 (1985)	llose-1,5-bisphosphate
	Л	Pongor S. and A.A. Szalay, "Prediction Polypeptides," Proc Natl Acad Sci U	S A. 82(2):366-70 (1985)	
	JJ	Prasher et al., "Sequence Comparison Biochemistry 26: 1326-1332 (1987)		
	ЛК	Prasher et al., "Primary structure of th 229-233 (1992)		•
	лL	Proudfoot, A.E.I. et al., "Strategies for Chemokine Antagonists as Therapeutics", Seminars in Immunology, 15: 57-65 (2003)		
	ЛМ	Puhlmann et al. "Thymidine kinase-de phosphorylase as a vector for tumor-d	irected gene therapy." Hum Ger	ne Ther. 10(4):649-57 (1999)
	JN	Quenelle, D.C. et al., "Efficacy of Multiple- or Single-Dose Cidofovir against Vaccinia and Cowpox Virus Infections in Mice", Antimicrobial Agents and Chemotherapy, 47(10): 3275-3280 (2003)		
	JO	Ramirez, J.C. et al., "Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration", Arch. Virol., 148: 827-839 (2003)		
	ЛР	Rangarajan, A. and R.A. Weinberg, "Comparative biology of mouse versus human cells: modeling human cancer in mice", Nature Reviews Cancer, 3: 952-959 (2003)		
	JQ	Ransohoff, R.M. et al., "Three or more routes for leukocyte migration into the central nervous system", Nat. Rev. Immunol., 3: 569-581 (2003)		
	JR	Reddy et al. "Folate-mediated targetin Drug Carrier Syst. 15(6):587-627 (199	g of therapeutic and imaging ag	
	JS	Reno, F., "Non-clinical Toxicology", I Fletcher et al.(eds.), ch.6: 55-64 (c200		naceutical Medicine, A.J.
	JT	Ribas, A. et al., "Current Developmen of Clinical Oncology, 21(12): 2415-24	ts in Cancer Vaccines and Cellu	lar Immunotherapy", Journal
	JU	Ring, C.J.A., "Cytolytic viruses as pot	<del>_</del>	
	JV	Rodriguez, J.F. et al., "Expression of t gene marker to follow virus dissemina U.S.A., 85: 1667-1671 (1988)	tion in tissues of infected anima	lls," Proc. Natl. Acad. Sci.
	JW	Rothenberg, M.L. et al., "Improving the opportunities", Nat. Rev. Cancer, 3: 30	03-309 (2003)	
	JX	Ruef et al. "Sternal wound infection at carriage of Staphylococcus aureus" J. (1996)		
	JY	Santoro, J. and M.E. Levison, "Rat Mo 915-918 (1978)	odel of Experimental Endocardi	tis," Infect. Immun. 19(3):
	JZ	Schlör et al., "In vivo and in vitro stud (HlyA) secretion machinery of Escher		
	KA	Schmidt et al. "Generation of effective using adenovirus-enhanced transferrin	cancer vaccines genetically en	gineered to secrete cytokines

Examiner Signature	Date Considered	
EXAMINER: Initial if citation considered, whether or not citation is in c	onformance with MPEP 609; Draw line through citation if not in	
conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute For (Modified)	m PTO-1449	9 U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002	Application No. 10/849,664
(		, diamana wasanam amaa	17240-004002	10/849,004
l ist of P	atonte an	d Publications for Applicant's	Applicant	
		n Disclosure Statement	Szalay, et al.	
			Filing Date	Group Art Unit
(37 CFR §1.98			May 19, 2004	1632
	Other D	ocuments (include Author, 7	<u> Fitle, Date, and Place o</u>	f Publication)
Examiner Initial	Desig. ID		Document	
·		Shapiro, D. and A.W. Fox, "Biotechno		opment", Principles and
	КВ	Practice of Pharmaceutical Medicine, Sons		
		Shariatmadari et al., "Improved techni	ique for detection of enhanced g	reen fluorescent protein in
	KC	transgenic mice," Biotechniques 30:12	282-1285 (2001)	
	KD	Shata, M.T. et al., "Optimization of re Methods, 283: 281-289 (2003)	combinant vaccinia-based ELIS	POT assay", J. Immunological
,	KE	Shenk, T., "Delivery systems for gene		
		Therapy, Quesenberry, P.J. et al. (Eds Shepherd, A.J., "Good Laboratory Pra	.), ch.6: pp 161-1/8, c1998 Wile	conment Laboratory" Gene
	KF	Therapy Technologies, Applications a		
		Wiley & Sons Ltd.		
	KG	Shimizu, Y. et al., "Immunotherapy of tumor-bearing mice utilizing virus help", Cancer Immunol.		
		Immunother., 27: 223-227 (1988) Sinkovics, J. and J. Horvath, "New Developments in the Virus Therapy of Cancer: A Historical		
	KH	Review", Intervirology, 36: 193-214 (1993)		
	KI	Sinkovics, J.G. and J.C. Horvath, "Newcastle disease virus (NDV): brief history of its oncolytic		
	- Kı	strains", J. Clin. Virol., 16: 1-15 (2000	0)	( ) D 1 12 421
	KJ	Sinkovics, J.G. and J.C. Horvath, "Vir 432 (2003)		
	KK	Smee, D.F. and R.W. Sidwell, "A revi		ti-orthopoxvirus activity in
		animal models", Antiviral Research, 5 Smee, D.F. et al., "Effects of cidofovir		voccinio vinus respiratory
	KL	infection in mice", Antivir. Res., 52: 5		vaccina vitus respiratory
	KM	Smith, G.L. and B. Moss, "Infectious	poxvirus vectors have capacity i	for at least 25000 base pairs of
	KIVI	foreign DNA", Gene, 25: 21-28 (1983		
	KN	Smith, G.L. et al., "The formation and Virol., 83: 2915-2931 (2002)	l function of extracellular envelo	pped vaccinia virus", J. Gen.
		Somia, N. and I.M. Verma, "Gene The	erapy: Trial and Tribulations". N	Jat. Rev. Genet., 1(2): 91-99
	ко	(2000)		
		Spencer et al., "Unilateral Transplanta		
	KP	Nucleus Of Patients with Parkinson's	Disease", New England Journal	of Medicine 327: 1541-1548
		(1992) Stehle, G. et al., "Plasma protein (albu	umin) catabolism by the tumor it	selfimplications for tumor
	KQ	metabolism and the genesis of cachex		
	`	(1997)		
	KR	Stojdl, D.F. et al., "VSV strains with o		vn innate immunity are potent
		systemic anti-cancer agents", Cancer C Sudimack et al. "Targeted drug delive		Drug Deliv Rev. 41(2):147-62
}	KS	(2000)	ry via the rotate receptor. Adv	Diug Deliv Nev. 41(2).147-02
	νт	Sutton et al. "In vivo adenovirus-medi	iated suicide gene therapy of ort	hotopic bladder cancer." Mol
	KT	Ther. 2(3):211-7 (2000)	-	

Examiner Signature	Date Considered	
EXAMINER: Initial if citation considered, whether or not citation is in co	onformance with MPEP 609; Draw line through citation if not in	
conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute For (Modified)	m PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement		Applicant Szalay, et al.		
(37 CFR §1.98	R(b))		Filing Date May 19, 2004	Group Art Unit 1632
		ocuments (include Author,		f Publication)
Examiner	Desig.			
Initial	ID		Document	
	KU	Suzuki M., Szalay A.A., "Bacterial tra peptidoglycan synthesis," Methods Er	nzymol. 68:331-342 (1979)	
	KV	Suzuki, S. et al. "Coexpression of the specific antigen promoter-driven suici concentrations," Cancer Research 61(	ide gene therapy for prostate can 4):1276-1279 (2001)	cer cells at low testosterone
	KW	Symons, J.A. et al., "A study of the va virulence", Journal of General Virolog	gy, 83: 1953-1964 (2002)	
	KX	Szalay A.A. et al., "Separation of the gels," Nucleic Acids Res. 4(5):1569-7	complementary strands of DNA	fragments on polyacrylamide
	KY	Szalay A.A .et al, "Genetic engineering Sci. 14:321-32 (1979)	ng of halotolerance in microorga	·
	KZ	Technology Evaluation Center, "Spec Melanoma", TEC Assessment Program	m, 16(4): 1-46 (2001)	
	LA	t'Hart, B.A. et al., "Gene thereapy in n Gene Therapy, 10: 890-901 (2003)	nonhuman primate models of hu	man autoimmune disease",
Theuer e		Theuer et al., "A recombinant form of		
	LB	factor receptor that is cytotoxic witho 16872-16877 (1992)		
	LC	Timiryasova, T.M. et al., "Antitumor Research, 11(3): 133-144 (1999)		
		Timiryasova, T.M. et al., "Replication		
	LD ·	exogenous gene expression mediated by PUV-inactivated virus in glioma cells", Journal of Gene Medicine, 3: 468-477 (2001)		
	LE	Timiryasova, T.M. et al., "Vaccinia vi cell growth and induces apoptosis." In	nt J Oncol. 14(5):845-54 (1999)	
		Timiryasova, T.M. et al., "Visualization		
	LF	GFP Fusion Protein", Bioluminescence Symposium on Bioluminescence Cher		
	2.	Grove, Monterey, California: Septemb		
The state of the		Publishing Co. (c2001), pages 457-46		
	LG	Timpl, "Antibodies to Collagens and I	Procollagens," Methods Enzymo	ol. 82: 472-498 (1982)
	LH	Tjuvajev, J. et al., "Salmonella-based expression therapy (TAPET™) for dia		
	LI	Toguchi et al., "Suicide Gene Therapy Replication Competent Vaccinia Virus Eleventh International Conference on California	of C6 Glioma Cells Mediated loss," Cancer Gene Therapy 10:	by Replication-Deficient and S32 (2003) presented at the
	IJ	Tokugawa et al., "A model system for novel secretion promoting factor whic		
	LK	Tokugawa et al., "A novel protein secu Escherichia coli," J.Biotechnol. 35: 69	retion factor from a Vibrio spec	
	LL	Tonetti DA et al "Stable transfection of breast cancer cells," J Steroid Biocher	of an estrogen receptor beta cDN	
Examiner Sign	ature		Date Considered	
EXAMINED: 1	nitial if aitatia	on considered, whether or not citation is in co	informance with MPEP 600: Describe	e through citation if not in
		dered. Include copy of this form with next co		anough distant intern

Substitute For (Modified)	m PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002	Application No. 10/849,664
		d Publications for Applicant's n Disclosure Statement	Applicant Szalay, et al.	
			Filing Date	Group Art Unit
(07 OFD 64 OF	VL \\		May 19, 2004	1632
(37 CFR §1.98		companie (include Author 7		<u> </u>
		ocuments (include Author, 1	itte, Date, and Place o	T Publication)
Examiner Initial	Desig. ID		Document	
	LM	Tresco et al., "Polymer-encapsulated l Lesion-Induced Rotational Behavior",	, Cell Transplantation 1:255-264	(1992)
	LN	Tscharke, D.C. et al., "A model for va injection of mouse ear pinnae", J. Gen	n. Virol., 80: 2751-2755 (1999)	
	LO	Tscharke, D.C. et al., "Dermal infection using other inoculation routes", Journal	al of General Virology, 83: 197	7-1986 (2002)
	LP	Tseng, JC. et al., "In Vivo Antitumor Cancer Institute, 94(23): 1790-1802 (2	2002)	
	LQ	Tseng, JC. et al., "Systemic tumor ta 22(1): 70-77 (2004)		
, , ,	LR	Tsung, K. et al., "Immune Response A Cyclophosphamide and IL-12", J. Imm		d by Treatment with
	LS	Vanderplasschen, A. et al., "Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation", Journal of General Virology, 78: 2041-2048 (1997)		
	LT	Vanderplasschen, A. et al., "Intracellular and extracellular vaccinia virions enter cells by different mechanisms", Journal of General Virology, 79: 877-887 (1998)		
	LU	Varghese, S. and S.D. Rabkin, "Oncol Cancer Gene Therapy, 9: 967-978 (20	lytic herpes simplex virus vector	rs for cancer virotherapy",
1	LV	Vento, S. and F. Cainelli, "Infections in prevention, and treatment", Lancet, 4:	in patients with cancer undergoi	ng chemotherapy: aetiology,
	LW	Vestweber, D., "Regulation of endother Cell Biol., 14: 587-593 (2002)	elial cell contacts during leukoc	yte extravasation", Curr. Opin.
	LX	Vile, R. et al., "The oncolytic virother biosafety points to consider", Cancer C		
	LY	Vogel, J.R., "Outsourcing Clinical Dra (CROs): Critical Success Factors", Pri Fletcher et al.(eds.), ch.40: 461-482 (c	inciples and Practice of Pharmac (2002) John Wiley & Sons Ltd.	ceutical Medicine, A.J.
	LZ	Voisey et al. Elimination of internal re (luxCDABE) operon." Biotechniques	24(1):56, 58 (1998)	
	MA	Wallack, M.K. et al., "A Phase III Rar Melanoma Oncolysate-Active Specific Cancer, 75(1): 34-42 (1995)	ndomized, Double-Blind, Multii c Immunotherapy for Patients w	ith Stage II Melanoma",
	МВ	Wallack, M.K. et al., "Increased Survi Vaccine", Annals of Surgery, 226(2):	198-206 (1997)	
	МС	Wallack, M.K. et al., "Surgical Adjuva Melanoma: The Final Analysis of Data Vaccinia Melanoma Oncolysate Trial"	a From a Phase III, Randomized ', J. Am. Coll. Surg., 187(1): 69	l, Double-Blind, Multicenter -79 (1998)
	MD	Wang Y. et al., "A study of protein-prenergy transfer (LRET) from <i>Renilla</i> 1 (2001)	otein interactions in living cells	using luminescence resonance

Examiner Signature	Date Considered	
EXAMINER: Initial if citation considered, whether or not citation is in co	onformance with MPEP 609; Draw line through citation if not in	
conformance and not considered. Include copy of this form with next communication to applicant.		

				Silect <u>16</u> 01 <u>19</u>
Substitute For (Modified)	m PTO-144	9 U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002	Application No. 10/849,664
		nd Publications for Applicant's on Disclosure Statement	Applicant Szalay, et al.	
(37 CFR §1.98	B(b))		Filing Date May 19, 2004	Group Art Unit 1632
(	Other D	ocuments (include Author,	Title, Date, and Place o	f Publication)
Examiner Initial	Desig. ID	·	Document	
	ME	Wang Y. et al., "Renilla luciferase- A for real-time imaging of gene express: 268(2):160-8 (2002)		
	MF	Wang, Y. et al., "The Renilla Lucifera Cells", Bioluminescence & chemilum Bioluminescence Chemiluminescence J.W. et al., John Wiley & Sons Ltd. (c	inescence: Proceedings of the 9te: Woods Hole, Massachusetts, C	th International Symposium on
	MG	Warrington et al. "Developing VDEP" Int J Radiat Oncol Biol Phys. 42(4):90	T for DT-diaphorase (NQO1) us 09-12 (1998)	
	МН	Wegner et al., "Cis-acting suquences in persistence in mouse cells: implication 17:9909-9932 (1989)	n of HMG-I in their function", N	Jucleic Acids Research
	MI	Weissleder et al. "Drug targeting in m 8(1):55-63 (1992)		
	MJ	Weissleder, T. et al., "In vivo magnetic resonance imaging of transgene expression", Nat. Med., 6(3): 351-354 (2000)		
	MK	Welling et al "Technetium-99m labell infections and sterile inflammations."		
	ML	Welling et al "Radiochemical and bio bacterial infections." Nucl Med Biol.		-UBI 29-41 for imaging of
	ММ	West et al. "Identification of a somato transferrin receptor." J Neurosci. 17(1		cytoplasmic domain of the
	MN	Wharton, M. et al., "Recommendation Program", MMWR, 52(RR-7): 1-16 (2		n a Pre-Event Vaccination
	МО	Whitley, R.J., "Smallpox: a potential a	agent of bioterrorism", Antiviral	Research 57: 7-12 (2003)
	MP	Williams J.G. and Szalay A.A., "Stab cyanobacterium Synechococcus R2,"	Gene. 24(1):37-51 (1983).	
	MQ	Winn et al., "Behavioral Recovery fol Cells", Experimental Neurology 113:3	322-329 (1991)	
	MR	Winn, S.R. et al., Polymer-encapsulate factor promote the survival of axotom Academy of Science, 91:2324-2328 (1	ized septal cholinergic neurons,' 1994).	' Proceedings of the National
	MS	Wisher, M., "Biosafety and product re viruses", Cancer Gene Therapy, 9: 10:	56-1061 (2002)	
	МТ	Wittrup, D., "Tumor Targeting Theory Conference entitled Antibody Engine November 30 - December 3, 2003 - T	ering: Forging the Future of A he Paradise Point Resort - San D	Antibody Therapeutics, Diego, CA, pp. 1-17
	MU	Wlodaver, C.G. et al., "Laboratory-acc 1-5 (2003)	•	
	MV	Wong, M.M. and E.N. Fish, "Chemok Immunol. 15: 5-14 (2003)	ines: attractive mediators of the	immune response", Semin.

Examiner Signature	Date Considered	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Substitute For (Modified)	m PTO-144	9 U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17248-004002	Application No. 10/849,664
List of Patents and Publications for Applicant's Information Disclosure Statement			Applicant Szalay, et al.	
(37 CFR §1.98(b))			Filing Date May 19, 2004	Group Art Unit 1632
Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
	MW	Yadav, R. et al., "Migration of leukocytes through the vessel wall and beyond," Thromb. Haemost., 90: 598-606 (2003)		
	MX	Yansura, D.G. and Henner D.J., "Use of the Escherichia coli lac repressor and operator to control gene expression in Bacillus subtilis," Proc. Natl. Acad. Sci USA 81: 439-443 (1984)		
	MY	Yu Y.A., "Visualization of molecular and cellular events with green fluorescent proteins in developing embryos: a review," Luminescence. 18(1):1-18 (2003) Erratum in: Luminescence. 2003 Jul-Aug;18(4):243		
	MZ	Yu Y.A. et al., "A Renilla luciferase-Aequorea GFP (ruc-gfp) fusion gene construct permits real-time detection of promoter activation by exogenously administered mifepristone in vivo," Mol Genet Genomics. 268(2):169-78 (2002)		
	NA	Yu Y.A. et al., "Optical imaging: bacteria, viruses, and mammalian cells encoding light-emitting proteins reveal the locations of primary tumors and metastases in animals," Anal Bioanal Chem. 377(6):964-72 (2003)		
	NB	Yu, Y.A. et al. "Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins," Nat Biotech. 22(3): 313-320 (2004)		
	NC	Yun A.C. et al. "Nitrogenase promoter-lacZ fusion studies of essential nitrogen fixation genes in Bradyrhizobium japonicum I110," J Bacteriol. 167(3):784-91 (1986)		
	ND	Zamir et al. "Stable chromosomal integration of the entire nitrogen fixation gene clusterfrom Klebsiella pneumoniae in yeast," Proc Natl Acad Sci U S A. 78(6):3496-500 (1981)		
	NE	Zaucha, G.M. et al., "The Pathology of Experimental Aerosolized Monkeypox Virus Infection in Cynomolgus Monkeys (Macaca fascicularis)", Lab. Invest., 81: 1581-1600 (2001)		
	NF	Zeh, H.J. and D.L. Bartlett, "Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers", Cancer Gene Therapy, 9: 1001-1012 (2002)		
	NG	Zhang et al., "Urothelium-specific Exp Formation of Carcinoma in Situ and In 3517 (1999)	avasive Transitional Cell Carcino	oma," Cancer Res.59: 3512-
	NH	Zhu et al., "Smad3 Mutant Mice Deve	lop Metastatic Colorectal Cancer	r," Cell 94: 703-714 (1998)
	NI	Zinkernagel, R.M., "Uncertaintiesdis 103-125 (2002)		_
	NJ	Zinn et al., "Simulataneous evaluation imaging," Nuclear Medicine and Biolo	pgy 28(2):135-144 (2001)	
	NK	Zinn et al. "Noninvasive monitoring of affinity peptide radiolabeled with 99m"		

Examiner Signature	Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.